迪卡斯

A phase 3 clinical trial led by Moffitt Cancer Center demonstrates that the melphalan hepatic delivery system significantly improves progression-free survival in patients with metastatic uveal melanoma to 9.1 months versus 3.3 months with standard care.

Delcath Systems received FDA clearance for its IND application to initiate a Phase 2 trial of Hepzato Kit in liver-dominant metastatic colorectal cancer (mCRC).